DomoSafety and Roche Pharma innovate in digital health

Please login or
register
14.01.2021
symbolic picture digital health

DomoSafety, a digital health leader offering a private cloud platform for patient monitoring and decision support for home care, has launched a pilot project with Roche Pharma (Switzerland) Ltd. The project aims at improving the quality of life of people living with Spinal Muscular Atrophy, a rare neuromuscular disease.

Spinal muscular atrophy (SMA) is a severe, inherited, progressive neuromuscular disease that causes devastating muscle atrophy and disease-related complications. It is the most common genetic cause of infant mortality and one of the most common rare diseases, affecting approximately one in 11,000 babies. SMA leads to the progressive loss of nerve cells in the spinal cord that controls muscle movement. Depending on the type of SMA, an individual’s physical strength and their ability to walk, eat or breathe can be significantly diminished or lost.

For people living with SMA, like many people with chronic conditions, digital health technologies bear the potential to monitor disease progression in real-life, continuously and holistically, and to provide solutions to support people in living an independent life and feeling safer and freer, at home and on the go.

The Ecublens (Vaud)-based startup DomoSafety has been at the forefront of innovation in patient monitoring and decision support for home care. It developed an AI-based Software-as-a-Service (SaaS) platform, which aggregates longitudinal behavioural and physiological data from multiple sources such as smartwatches, IoT (Internet of Things) platform or medical devices and analyses them in real-time using machine-learning techniques, making it possible to predict acute exacerbations of chronic diseases.

The algorithms in the SaaS platform were built using billions of behavioural and physiological data points collected during multiple clinical research studies conducted in collaboration with several Swiss university hospitals (CHUV, Lausanne and Inselspital, Bern) and internationally renowned institutes (EPFL, Lausanne and a bioengineering lab of Bern University). Adapted to SMA, this unique technology can transform the care of SMA patients and improve their safety and independence.

DomoSaftefy has now entered a partnership with the Pharma Giant Roche Switzerland to bring digital health solutions to SMA patients. As part of the collaboration, Roche supports a project during which DomoSafety will adapt its evolutive platform to the needs of SMA patients, allowing them to improve care by predicting or detecting early potential sudden health deteriorations. Patients will have access to their data in real-time through a mobile application, allowing them to monitor and potentially optimize their care and well-being. Alerts will be proactively or automatically triggered in case of an emergency.

(Press release/RAN)

0Comments

More news about

DomoHealth SA

Company profiles on startup.ch

DomoHealth SA

rss